LILRB2 and non-small cell lung carcinoma: Chen et al. found that the co-inhibition of ILT4 and PD-L1 demonstrated greater efficacy than PD-L1 inhibition alone in NSCLC, but, interestingly, this effect was negated in EGFR-mutant tumors [172].